Skip to main content
Atrás
Watch Compare

BriaCell Therapeutics Corp.

Calidad de datos: 83%
También listada como BCTXL Nasdaq BCTXZ Nasdaq
BCTX
Nasdaq Manufacturing Chemicals
$4.60
▲ $0.17 (3.84%)
Cap. Mercado: 33.21 M
Precio
$4.60
Cap. Mercado
33.21 M
Rango del Día
$4.33 — $4.61
Rango de 52 Semanas
$3.60 — $98.20
Volumen
192,824
Apertura $4.33
Promedio 50D / 200D
$4.16
10.68% above
Promedio 50D / 200D
$9.42
51.17% below

Quick Summary

Puntos Clave

Negative free cash flow of -31.42 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-149.82%
Below sector avg (-53.47%)
ROIC-120.91%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio10.10
Interest Coverage-831.19

Valoración

PE (TTM)
-1.12
Above sector avg (-1.47)
P/B Ratio1.10
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -1.1 -1.5
P/B 1.1 1.6
ROE % -149.8 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -29.64 M
ROE -149.82% ROA -127.01%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -31.42 M
ROIC -120.91% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.10
Interest Coverage -831.19 Asset Turnover N/A
Working Capital 28.99 M Tangible Book Value 30.21 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.12 Forward P/E N/A
P/B Ratio 1.10 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -94.63%
Market Cap 33.21 M Enterprise Value 3.30 M
Per Share
EPS (Diluted TTM) -63.33 Revenue / Share N/A
FCF / Share -4.35 OCF / Share -4.29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 106.03%
SBC-Adj. FCF -32.50 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -26.31 M -4.79 M -20.30 M -26.84 M
EPS (Diluted) -62.19 -0.29 -1.30 —
Gross Profit — — — —
Operating Income -27.20 M -33.33 M -23.27 M -15.29 M
EBITDA — — — —
R&D Expenses 21.27 M 27.18 M 15.34 M 8.02 M
SG&A Expenses — — — —
D&A — — — 15,272.0
Interest Expense 36,979.0 — 979.0 979.0
Income Tax — — — 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 21.65 M 5.87 M 27.16 M 42.58 M
Total Liabilities — — — —
Shareholders' Equity 17.33 M -2.68 M -3.78 M 10.33 M
Total Debt — — — —
Cash & Equivalents 10.49 M 862,089.0 21.25 M 41.04 M
Current Assets 19.93 M 3.65 M 26.95 M 42.35 M
Current Liabilities 3.98 M 7.46 M 1.80 M 941,087.0